Anna Dirner

Anna Dirner

Auto-generated profile, based on publicly available information

Anna Dirner

Genomate Health Inc, Cambridge, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in JCO Precision Oncology
Verified
Journal Article
Closed access
ÉRÉva Remenár
Éva Remenár
RDRobert Doczi
Robert Doczi
ADAnna Dirner
Anna Dirner
ASAnna Sipos
Anna Sipos
APAnita Perjési
Anita Perjési
IPIstván Peták
István Peták

30 May 2025 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
ADAnna Dirner
Anna Dirner
DKDóra Kormos
Dóra Kormos
DLDora Lakatos
Dora Lakatos
MBMárton Bolyácz
Márton Bolyácz
MKMária Kocsis-Steinbach
Mária Kocsis-Steinbach
IPIstván Peták
István Peták
Tumors harbor multiple genetic alterations, yet treatment decisions are commonly based on single biomarkers, leading to underutilization of genomic information by comprehensive molecular tests, uncertainty in clinical practice, and frequent treatment failures. Although molecular tumor boards can assist personalized treatments, this process is not scalable or standardized, resulting in highly discordant recommendations. Validated digital solutions for personalized decision support are highly needed. The Digital Drug Assignment (DDA) system is a computational reasoning model that scores treatment options based on the full tumor genomic data. We retrospectively analyzed data of 111 lung cancer patients and found that high-score MTAs (1000≦DDA score) provided significant clinical benefit over other treatments, in terms of ORR, PFS, and OS. These results demonstrate that the DDA system is predictive of relative benefit of the various agents used in lung cancer care. Digital drug assignment can potentially address challenges with complex molecular profiles in routine clinical settings.